KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.
Bimarzhan AssatovaRobert WillimChristopher TrevisaniGarrett HaskettKhyati Maulik KariyaKusha ChopraSung Rye ParkMichael Yevgeniy TolstorukovSean M McCabeJessica DuffyAbner LouissaintJani HuuhtanenDipabarna BhattacharyaMohamed El MissiryMin Jung KohFoster PowersElizabeth A MorganLei YangBrandy PinckneyMatthew J CottonAndrew CrabbeJessica Beth ZiembaIan BrainTayla B Heavican-ForalJaveed IqbalRonald NemecAnna Baird RiderJosie Germain FordMin Ji KohNora ScanlanThomas P LoughranThomas P LoughranWon Seog KimJaehyuk ChoiJuliette RoelsLena BoehmeTom PuttemanTom TaghonJeffrey A BarnesP Connor Connor JohnsonEric D JacobsenSteven A GreenbergDavid M WeinstockSalvia JainPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our findings suggest the potential benefit of a broader treatment strategy combining therapeutic antibodies with PI3Ki for the treatment of patients with mature T-cell and NK-cell neoplasms. See related commentary by Varma and Diefenbach, p. 2300.